Trial Profile

A Phase III Randomized, Open-Label Study of Docetaxel in Combination With CG1940 and CG8711 Versus Docetaxel and Prednisone in Taxane-Naive Patients With Metastatic Hormone-Refractory Prostate Cancer With Pain

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 27 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Prednisone (Primary) ; Tumour cell vaccine-GVAX (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Registrational; Therapeutic Use
Acronyms VITAL-2
Sponsors Cell Genesys

26 Feb 2009 Preliminary results were presented at ASCO Genitourinary Cancer Symposium 2009.
27 Aug 2008 Status changed from recruiting to discontinued according to a Cell Genesys media release.
23 Jul 2008 On track to complete enrolment in the first half of 2009 according to cell Genesys media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com